Blackbird invests in Heidi Health Trading Pty Ltd.
Funding Provisional 92% confidence first seen
Heidi Health Trading Pty Ltd. announced it raised $340 million in new funding to expand its AI Care Partner for healthcare providers worldwide. The round included a $100 million Series C led by Blackbird, alongside $240 million in growth investment from General Catalyst, with participation from existing investors including Phoenix Court, Point72 Private Investments, and Headline. The funding is intended to deepen deployment and adoption of AI agents within health systems, building on products such as Scribe and Evidence.
The deal
Heidi Health Trading Pty Ltd $340M Series C · announced 22 Sep 2026
Investors General Catalyst Blackbird
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Heidi Health Trading Pty Ltd. announced a $340 million financing to expand its AI Care Partner globally, including a $100 million Series C led by Blackbird and $240 million in growth investment from General Catalyst. The company said the capital will be used to deepen deployment and adoption of its AI agents in health systems, building on products such as Scribe and Evidence.
- Why it matters
- For healthcare and adjacent technology leaders, this signals that significant new capital is being directed toward clinical AI workflow tools, especially products focused on documentation automation and research support for clinicians. Decision-makers should care because well-funded vendors can accelerate product development, sales reach, and enterprise deployment capacity, which may affect partnership options, competitive positioning, and the pace at which health systems evaluate AI agent adoption.
- Evidence
- The event is supported by Heidi Health Trading’s announcement as reported by SiliconANGLE AI, which specified the total $340 million raise, the investor breakdown, and the stated use of funds. The available coverage is based on a single article and appears consistent within that report, but it does not provide independent verification beyond the company’s announcement.
- What remains uncertain
- It is unclear from the coverage what valuation, governance rights, revenue traction, customer deployment scale, or geographic rollout plans are tied to this financing. The report also does not verify how quickly the new capital will translate into measurable adoption inside health systems or how differentiated Heidi’s products are versus competing clinical AI tools.
- Monitor next
- Watch for disclosed health-system customer wins, deployment metrics, or regulatory/compliance milestones that show whether the new funding is converting into scaled enterprise adoption.
Analytical support, not advice — assumptions and open questions stated above.